Điều chế và kiểm tra chất lượng kháng thể đơn dòng gắn đồng vị phóng xạ I-rituximab dùng trong điều trị U Lympho ác tính không Hodgkin

Monoclonal antibody rituximab labeled with 131 I was used in the treatment of B cell non Hodgkin’s Lymphoma in targeted therapy. The radioiodinated rituximab was prepared using chloramin T and iodogen methods. The radioimmunoconjugated quality validation was performed using chemical tests such as fast protein liquid chromatography, radioautography, thin layer chromatography, paper chromatography and photon gamma ray spectrum. Biological evaluations of this radiopharmaceutical have tested for asepsis, bacterial endotoxin, invitro stabilities and biodistribution in normal mice. Labelling yields were 95% using chloramin T and more than 85% using iodogen methods. Specific activity of labelled compound from two methods are 0.246 GBq/mg and 0.037 GBq/mg. Radiochemical purity of labeled antibody was 98% and radionuclide purity was more than 99.9%. The entry rate of radioimmunoconjugation in tissue blood perfusion has a high distribution rate and has a rapid clearance by the renal route. The 131 I-rituximab has passed the testing requirements for radiopharmaceutical therapy and for clinical use.

Title:	Điều chế và kiểm tra chất lượng kháng thể đơn dòng gắn đồng vị phóng xạ I-rituximab dùng trong điều trị U Lympho ác tính không Hodgkin
Authors:	Nguyễn, Thị Thu Mai, Trọng Khoa Trần, Đình Hà Võ, Thị Cẩm Hoa Dương, Văn Đông Bùi, Văn Cường Nguyễn, Thị Khánh Giang
Keywords:	Radioimmunotherapy, I-rituximab, Quality Control of Radiopharmaceuticals
Issue Date:	2013
Publisher:	H. : ĐHQGHN
Citation:	8 tr.
Abstract:	Monoclonal antibody rituximab labeled with 131 I was used in the treatment of B cell non Hodgkin’s Lymphoma in targeted therapy. The radioiodinated rituximab was prepared using chloramin T and iodogen methods. The radioimmunoconjugated quality validation was performed using chemical tests such as fast protein liquid chromatography, radioautography, thin layer chromatography, paper chromatography and photon gamma ray spectrum. Biological evaluations of this radiopharmaceutical have tested for asepsis, bacterial endotoxin, invitro stabilities and biodistribution in normal mice. Labelling yields were 95% using chloramin T and more than 85% using iodogen methods. Specific activity of labelled compound from two methods are 0.246 GBq/mg and 0.037 GBq/mg. Radiochemical purity of labeled antibody was 98% and radionuclide purity was more than 99.9%. The entry rate of radioimmunoconjugation in tissue blood perfusion has a high distribution rate and has a rapid clearance by the renal route. The 131 I-rituximab has passed the testing requirements for radiopharmaceutical therapy and for clinical use.
URI:	http://repository.vnu.edu.vn/handle/11126/12999
Appears in Collections:	Natural Sciences and Technology